Peroxisome proliferator-activated receptors (PPARs) are central regulators of lipoprotein metabolism and glucose homeostasis that are considered particularly useful for improving glycemic control and co morbidities in patients with type II diabetes mellitus. Clinical trials of PPAR-α agonists have demonstrated efficacy in reducing cardiovascular events; however, these benefits have been confined to subgroups of patients with low levels of high-density lipoprotein cholesterol or high levels of triglycerides. While activators of PPAR-γ reduce early atherosclerotic lesions and reduce cardiovascular events, these agents have the effect of increasing fluid retention in patients, which results in more hospitalizations for congestive heart failure. The PPAR α / γ dual agonists are developed to increase insulin sensitivity and simultaneously prevent diabetic cardiovascular complications. Such compounds are under clinical trials and proposed for treatment of type II diabetes with secondary cardiovascular complications. However, PPAR α / γ dual agonists such as muraglitazar, tesaglitazar and ragaglitazar have been noted to produce several cardiovascular risks and carcinogenicity, which raised number of questions about the clinical applications of dual agonists in diabetes and its associated complications. Therefore future studies of PPAR-γ agonists or dual PPAR-α/γ agonists will require further delineation of the risk profile to avoid adverse outcomes in susceptible patients.
Introduction
Identification of molecular mechanisms of the transducer proteins involved in metabolic and anabolic pathways is crucial for understanding the energy homeostasis in the human body and to develop new therapeutic agents for the treatment of chronic metabolic disorders such as, Metabolic syndrome, obesity, atherosclerosis. 
